Caricamento quotazioni...
Previsioni
Il prezzo obiettivo medio degli analisti è 32,80 € (+27.233,33%). La mediana è 32,80 € (+27.233,33%).
| Acquista |
4 |
| Mantieni |
1 |
| Vendi |
0 |
Notizie Vai al feed delle notizie
BiomX subsidiary Zorronet launches mobile command app – shares near 52-week low
Zorronet, a subsidiary of BiomX, has released a mobile app for its command-and-control system on the Google Play Store and Apple App Store. The application aggregates cameras, sensors, drones and IoT data into structured alerts, uses AI for real-time classification and is already in use by cities, regional authorities and Israel Railways. BiomX shares trade at $0.64, close to their 52-week low; the company reports high cash burn, a negative EPS and a weak financial-health rating. Analyst notes point to possible undervaluation, while profitability is not expected this year. » Altro su de.investing.com
BiomX approves 2026 equity incentive plan and announces strategy updates
BiomX shareholders approved the "BiomX Inc. 2026 Equity Incentive Plan," authorizing issuance of up to 1,390,000 common shares and allowing an automatic 4% annual increase over ten years. An adjournment resolution was also adopted but was not needed because sufficient votes were present. BiomX announced an option agreement to acquire DFSL, the appointment of Dr. Ehud Levi to the board, and the amendment of existing warrants (exercise price $1.00, term one year); the NYSE American issued a non‑compliance notice due to insufficient shareholder equity. » Altro su de.investing.com
T3 Defense sells ZorroNet to BiomX for shares and promissory note
T3 Defense’s indirect subsidiary Water IO transferred 100% of ZorroNet to BiomX. In return, BiomX issued 1,300,000 common shares to Water IO (about 16.57% post-transaction) and issued a non-convertible promissory note for USD 1.25 million with a three‑month term; a performance-based earn-out was also agreed, payable by no later than 31 March 2027. ZorroNet provides AI-based computer-vision and autonomous surveillance solutions for defense and critical infrastructure; T3 Defense remains the indirect beneficial owner of the BiomX shares and simultaneously reported further balance-sheet and legal developments. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 290,9K | - |
| Utile lordo | 84,99K | 134,31% |
| Utile netto | -3,31 Mln | 35,47% |
| EBITDA | -3,34 Mln | 31,02% |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 1,21 Mln € |
Numero di azioni | 10,15 Mln |
Massimo/minimo a 52 settimane | 10,61 € - 0,10 € |
| Dividendi | No |
Beta | 1,37 |
Rapporto P/E | -0,01 |
Rapporto PEG | 0,00 |
Rapporto P/B | 0,13 |
Rapporto P/S | 4,23 |
Profilo aziendale
BiomX Inc., ein Mikrobiom-Unternehmen in der klinischen Phase, entwickelt Produkte, die natürliche und künstlich hergestellte Phagen-Technologien nutzen, um bestimmte schädliche Bakterien zu bekämpfen und abzutöten. Es zielt auf Bakterien ab, die das Erscheinungsbild der Haut beeinträchtigen, sowie auf chronische Krankheiten wie entzündliche Darmerkrankungen (IBD), primär sklerosierende Cholangitis (PSC), zystische Fibrose (CF), atopische Dermatitis und Darmkrebs (CRC). Das Unternehmen entwickelt BX004, eine Phagentherapie für Mukoviszidose-Patienten mit chronischen Atemwegsinfektionen durch Pseudomonas aeruginosa, die sich in klinischen Studien der Phase 1b/2a befindet. Zu den Pipeline-Produkten des Unternehmens gehören auch BX005, ein topischer Phagen-Cocktail, der sich in einer klinischen Studie der Phase 1/2 befindet und auf Staphylococcus aureus (S. aureus) abzielt, ein Bakterium, das mit der Manifestation der Krankheit in Verbindung gebracht wird, sowie BX003, ein oral verabreichter Phagen-Cocktail, der sich in der Phase 1b/2a befindet und auf ein bakterielles Ziel abzielt, das im Darm von IBD- und PSC-Patienten vorhanden ist. Darüber hinaus arbeitet das Unternehmen an einem Programm zur Behandlung von Darmkrebs, bei dem speziell entwickelte Phagen mit verschiedenen Nutzlasten eingesetzt werden, die intravenös verabreicht werden, um Bakterien des Typs Fusobacterium nucleatum, die sich in der Mikroumgebung des Tumors befinden, zu bekämpfen. BiomX Inc. wurde 2015 gegründet und hat seinen Hauptsitz in Ness Ziona, Israel.
| Nome | BIOMX INC. DL -,0001 |
| CEO | Michael Oster |
| Sede centrale | Dover,
de Stati Uniti |
| Sito web | |
| Settore | Beni di prima necessità |
| Industria | Prodotti alimentari |
| Quotazione in borsa | 27/01/2021 |
| Dipendenti | 20 |
Simboli di borsa
| Borsa | Simbolo |
|---|---|
AMEX | PHGE |
AMEX | PHGE-UN |
Scopri gli asset
Gli azionisti di BIOMX INC. DL -,0001 investono anche nei seguenti asset



